Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients
MetadatosMostrar el registro completo del ítem
AutorCarrillo, Esmeralda; Prados, José; Marchal Corrales, Juan Antonio; Boulaiz, Houria; Martínez, Antonio; Rodríguez-Serrano, Fernando; Caba Pérez, Octavio; Serrano Ortega, Salvio; Aránega Jiménez, Antonia
Hindawi Publishing Corporation; IOS Press
Polymerase chain reactionCirculating tumor cellsMessenger RNAReverse transcriptaseMelanomaCutaneous melanomaResidual diseaseClinical stageReaction assayMarker
Carrillo, E.; et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Disease Markers, 22(3): 175-181 (2006). [http://hdl.handle.net/10481/32689]
PatrocinadorThis study was supported by the Fondo de Investigación Sanitaria de la Seguridad Social (FIS), Spain through no. PI041372.
Malignant melanoma (MM) prognosis has been related to tumour thickness and clinical stage and metastasis risk has been associated with presence of tumour cells in peripheral blood. The aim of this study was to determine the relationship between presence of tyrosinase in peripheral blood of MM patients and their clinical prognosis. Blood samples from 58 MM patients (stage I–IV) were analysed, using RT-PCR assay to detect tyrosinase mRNA. The results showed that positive RT-PCR assay for tyrosinase were significantly associated with clinical status and tumour thickness. After a median follow-up of 24 months, RT-PCR results were found to be significant correlated with recurrence (p < 0.05) and clinical stage III (p < 0.05). Separate analysis of stage III tumours to determine the prognostic value of tyrosinase presence in peripheral blood showed an overall 24-month survival rate of 70% in the RT-PCR negative group versus 10% in the positive group (p < 0.02). These results suggest that detection of circulating melanoma cells may be especially relevant in stage III patients, in whom RT-PCR positivity defines a subpopulation at high risk of recurrence.